Novel Mechanism of Action Targeting Toxic Oligomers: Their lead candidate, CT1812, employs a unique mechanism by modulating the sigma-2 (S2) receptor to displace neurotoxic Aβ oligomers, offering a differentiated approach to neurodegenerative disease treatment compared to plaque-centric strategies.

Oral Small Molecule Convenience: CT1812's oral administration as a small molecule offers significant patient convenience and potentially higher compliance compared to the intravenous infusions required by many competing biologics in the neurodegenerative space.

Broad Pipeline Potential Beyond Alzheimer's: The foundational mechanism targeting neurotoxic oligomers gives CT1812 and future compounds potential applicability across multiple neurodegenerative diseases, including Parkinson's disease and Dementia with Lewy Bodies, which are already in their clinical pipeline.